Involved pharmaceutical companies in the Rheumatoid Arthritis market are Ablynx, Cyclone, Oryn Therapeutics, Kymera Therapeutics, and many others.
DelveInsight’s “Rheumatoid Arthritis Pipeline Insight, 2021” highlights the details around Rheumatoid Arthritis which is a long-term condition that causes pain, swelling, and stiffness in the joints. The condition usually affects the hands, feet, and wrists.
The Rheumatoid Arthritis report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The report also highlights the unmet needs concerning the development of Rheumatoid Arthritis.
Some of the key highlights of the Rheumatoid Arthritis Pipeline report–
- Taisho Pharmaceutical in October 2019, initiated an Extension Study of TS-152 in Subjects With Rheumatoid Arthritis.
- Ablynx announced that its anti-TNFα Nanobody, ozoralizumab (ATN-103), for the treatment of inflammatory diseases, showed excellent safety and efficacy results in the 48-week open-label extension (OLE) study of the worldwide and Japanese Phase II trials in the treatment of patients with Rheumatoid Arthritis (RA) who have an insufficient response to methotrexate alone.
- Key companies involved in the Rheumatoid Arthritis Pipeline are Ablynx, Cyclone, Oryn Therapeutics, Kymera Therapeutics, and many others.
- Key pipeline therapies expected to get launched include Ozoralizumab, Rabeximod, ORTD 1, KT 474, and many others
Request for Sample @ Rheumatoid Arthritis Pipeline Insights
Rheumatoid arthritis is a long-term condition that causes pain, swelling, and stiffness in the joints. The condition usually affects the hands, feet, and wrists. Rheumatoid arthritis is an autoimmune disease in which the immune system (which usually fights infection) attacks the cells that line the joints by mistake, making the joints swollen, stiff, and painful.
Rheumatoid Arthritis Emerging Therapies: Drug Profile
Ozoralizumab (as known as ATN-103) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases and is developed by Ablynx. In addition, it is a trivalent, bispecific nanobody that potently neutralizes TNF and binds to human serum albumin to increase its in vivo half-life.
Know More Information @ Rheumatoid Arthritis Pipeline Drugs
Key Pipeline Therapies along with companies
- Ozoralizumab: Ablynx
- Rabeximod: Cyxone
- ORTD 1: Oryn Therapeutics
- KT 474: Kymera Therapeutics
By Product Type
- Phase I
- Phase II
- Phase III
By Route of Administration
By Molecule Type
- Small Molecule
- Gene Therapy
- Stem Cell Therapy
By Mechanism of Action
- Protease Inhibitors
- Immune System
Contact Here for More Information @ Rheumatoid Arthritis Pipeline Assessment
Scope of the Rheumatoid Arthritis Pipeline Report
- Coverage- Global
- Key Market Players– Ablynx, Cyxone, Oryn Therapeutics, Kymera Therapeutics, and many others
- Key Rheumatoid Arthritis Pipeline Therapies- Ozoralizumab, Rabeximod, ORTD 1, KT 474, and many others.
Following is the Table of content of the Rheumatoid Arthritis Pipeline Report
|3||Rheumatoid Arthritis (RA): Overview|
|6||Rheumatoid Arthritis (RA): DelveInsight’s Analytical Perspective|
|7||In-depth Commercial Assessment|
|8||Rheumatoid Arthritis (RA) Collaboration Deals|
|9||Late Stage Products (Phase III)|
|11||Mid Stage Products (Phase III)|
|12||ABX464: Abivax S.A.|
|13||Dazodalibep: Viela Bio|
|14||Pre-clinical and Discovery Stage Products|
|15||Research Program: Rheumatoid Arthritis (RA) Therapeutics: twoXAR|
|17||Rheumatoid Arthritis (RA) Key Companies|
|18||Rheumatoid Arthritis (RA) Key Products|
|19||Rheumatoid Arthritis (RA) Unmet Needs|
|20||Rheumatoid Arthritis (RA) Market Drivers and Barriers|
|21||Rheumatoid Arthritis (RA) Future Perspective and Conclusion|
|22||Rheumatoid Arthritis (RA) Analyst Views|
|23||Rheumatoid Arthritis (RA) Key Companies|
Know more of what’s covered in the Rheumatoid Arthritis Pipeline Assessment report
Key Questions Answered in the Rheumatoid Arthritis report-
- How many companies are developing Rheumatoid Arthritis Drugs?
- How many Rheumatoid Arthritis (RA) drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Rheumatoid Arthritis (RA)?
- What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Rheumatoid Arthritis (RA) therapeutics?
- What are the recent trends, drug types, and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Rheumatoid Arthritis (RA) and their status?
- What are the key designations that have been granted to the emerging drugs?
Request for demo @ Rheumatoid Arthritis Pipeline and get a walk-through of our report
DelveInsight’s Diabetes Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’s Heart Failure Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’s Irritable Bowel Syndrome Market Insights, Epidemiology and Market Forecast – 2030 report.
DelveInsight’s Sleep Apnea Market Insights, Epidemiology and Market Forecast – 2030 report.
Visit on our blog section-
- Types and Treatment | Diabetes Symptoms and Risk Factors
- FDA approval to Ibsrela for Irritable Bowel Syndrome
- Sleep Disorders Types and Treatment Options
DelveInsight is a leading Business Consultant & Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end-to-end comprehensive solutions to improve their performance. Get hassle-free access to all the healthcare & pharma market research reports through our subscription-based platform PharmDelve.
Shruti Thakur [email protected]